Education only · provider review required

Thymosin alpha-1 · Immune-research context

An immune-modulating peptide approved in some countries and not in the US.

Medically reviewed by Bernard Garcia, MD

What it is

Thymosin alpha-1 (Tα1) is a peptide originally isolated from thymus tissue and studied for its effects on immune cell function. It is approved as a prescription medicine in several countries (for example for chronic hepatitis B and as a vaccine adjunct) under the name Zadaxin, but it is not FDA-approved in the United States.

Interest rose sharply during the COVID-19 pandemic; the resulting trials were mixed and small.

How it works

Research describes effects on T-cell maturation and dendritic-cell activity. Human trials exist for specific infectious and oncology contexts abroad. General "immune support" in healthy adults has not been studied in a way that supports a claim.

Research status

Research area Status
Chronic hepatitis B (outside the US) Approved in some countries
Oncology adjunct research Human trials abroad, mixed
General immune support in healthy adults Not established
Regulatory status (US FDA) Not an FDA-approved drug

Status reflects published research context only and is not a statement of safety, efficacy, or suitability for any person.

Frequently asked questions

Is thymosin alpha-1 approved anywhere?

Yes, in several countries outside the United States, for specific indications. It is not FDA-approved.

Is it the same as TB-500?

No. They are different peptides from different research areas — alpha-1 in immunology, beta-4 (TB-500) in tissue repair.

Can a US provider prescribe it?

Compounding access has been restricted by federal rule-making. A provider will explain the current position; this site does not recommend it.

Next step

Next step: a 3-minute confidential intake, reviewed by a licensed provider. No treatment is promised or implied.

Discuss with a provider

Free · about 10 minutes · reviewed by a licensed physician

General education · Not medical advice · Provider approval required